Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2015-10-25 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 3B and Section 708A Notice 14 pages 340.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, including ordinary shares and unlisted options. It contains detailed information about the number and terms of securities issued, issue prices, purpose of the issue, shareholder approvals, and quotation application for the securities on the ASX (Australian Securities Exchange). The document is regulatory in nature, focused on capital raising and securities issuance, and does not contain financial statements or management discussion. It is not an annual report, earnings release, or management report. It is a formal announcement of a capital raising event and securities issuance, consistent with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-10-25 English
Appendix 3B - Loyalty Option Issue 12 pages 289.4KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. It details the class and number of securities issued, terms of the securities, issue price, purpose, shareholder approvals, and quotation agreements. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issuance, consistent with a capital raising announcement rather than a brief notice or a report publication announcement.
2015-10-22 English
Prospectus for Placement & Loyalty Options 37 pages 2.5MB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Prospectus' and details a non-renounceable bonus issue of Loyalty Options and Placement Options by Imugene Limited. It includes information about the terms of the issue, important dates, risk factors, and legal notices. The document is a formal offer to shareholders regarding new securities issuance, including details on the capital structure and the rights attached to the options. It is not a financial report, earnings release, or management discussion, but rather a formal offer document for a share issue. This fits the definition of a Share Issue/Capital Change announcement.
2015-10-22 English
Letter to Option Holders 1 page 57.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a letter from Imugene Limited dated 23 October 2015, addressing option holders about the eligibility for a bonus options issue. It discusses the terms of the bonus options, the record date, and instructions for exercising options. There is no financial data, no report attached or referenced as being published, and no mention of an annual or interim report. The content is an announcement related to a capital change event (issue of bonus options). Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is short and focused on the capital change, not a full report or regulatory filing.
2015-10-22 English
AGM Corporate Presentation 15 pages 6.9MB
AGM Information Classification · 95% confidence The document is titled 'Corporate Presentation AGM 2015' and contains detailed information about the company's business, clinical trials, leadership, investment highlights, and product pipeline. It is structured as a presentation with slides, including company history, clinical status, and leadership profiles. The presence of 'AGM 2015' in the title strongly indicates that this document is a presentation prepared for the Annual General Meeting. There are no detailed financial statements or audit information that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor an announcement of voting results or capital changes. The content is consistent with an investor or shareholder presentation given at an AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (12,611 characters) supports it being a full presentation rather than a brief announcement.
2015-10-14 English
Results of Meeting 1 page 60.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF ANNUAL GENERAL MEETING' and provides detailed voting results for resolutions considered at the AGM held on 15th October 2015. It includes vote counts for each resolution, percentages, and notes on proxy votes and special resolution thresholds. There is no financial data or report content, only the official announcement of voting outcomes from the AGM. The document length is 2777 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-10-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.